Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02931838 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
A Phase 2 study of Psoriasis, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 268
- Enrollment target
- 20
- Study locations
NCT02931838: Completed Phase 2 study of Psoriasis, sponsored by Bristol-Myers Squibb.
NCT02931838 is a Phase 2 study of Psoriasis that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 268 participants, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (45% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02931838, a Phase 2 study of Psoriasis, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 268 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Study to evaluate efficacy and safety in subjects with moderate to severe Psoriasis treated with BMS-986165
Primary Outcome
Psoriasis Area and Severity Index (PASI) 75 response: patients who achieved ≥ 75% improvement (reduction) in PASI score compared to baseline were defined as PASI 75 responders. PASI scores can range from 0, corresponding to no signs of psoriasis up to theoretical maximum of 72.0, which means a higher PASI score reflects a higher psoriasis activity.
Conditions Studied
Interventions
- DRUG BMS-986165
- DRUG Placebo for BMS-986165
Study Locations (20)
North Carolina
- Piedmont Plastic Surgery & Dermatology - Charlotte/Blakeney Location - Charlotte
- PMG Research of Rocky Mount, LLC - Rocky Mount
- PMG Research of Wilmington, PLC - Wilmington
California
- University of California Irvine - Irvine
- University of California San Diego - San Diego
Illinois
- PMG Research of Christie Clinic, LLC - Champaign
- NorthShore University Health System - Skokie
Tennessee
- Rivergate Dermatology Clinical Research Center, Pllc - Goodlettsville
- Local Institution - Knoxville
Florida
- Renstar Medical Research - Ocala
Georgia
- Dermatologic Surgery Specialists, PC - Macon
Indiana
- Dawes Fretzin Clinical Research Group, LLC - Indianapolis
New Hampshire
- Dartmouth-Hitchcock Medical Center-Norris Cotton Cancer Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 268 participants |
| Start Date | 2016-11-15 |
| Est. Completion | 2017-11-16 |
| Phase | Phase 2 |
What the finished NCT02931838 record still lists
NCT02931838 is an interventional study that assigns participants to a tested intervention. The registered 268 participants enrollment target is mid-sized for trials with a published cap, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (45% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which BMS-986165 is the first listed.
NCT02931838 names 20 study sites across 15 states, led by North Carolina, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT02931838 about?
NCT02931838 is a clinical study titled "Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis". A Study to evaluate efficacy and safety in subjects with moderate to severe Psoriasis treated with BMS-986165
What is the current status of trial NCT02931838?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 268 participants. The study started on 2016-11-15. Estimated completion is 2017-11-16.
What conditions does trial NCT02931838 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT02931838?
The interventions under investigation include: BMS-986165 (DRUG), Placebo for BMS-986165 (DRUG).
Who is sponsoring clinical trial NCT02931838?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02931838 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02931838's enrollment target sits among peer trials
268 31st of 125 higher than 95 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study in Participants With Moderate to Severe Psoriasis
COMPLETED · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)
COMPLETED · Phase 2
-
Etanercept With Tacrolimus for Psoriasis
COMPLETED · Phase 2
-
A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05000632 · 268 participants · NA
Smoke Free SafeCare: Establishing a Smoke Free Home in CPS-involved Families
- NCT05797831 · 268 participants · Phase 2
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
- NCT05997381 · 268 participants · NA
BioBrace® Implant for Arthroscopic Repair of Full Thickness Rotator Cuff Tears
- NCT06233461 · 268 participants · Phase 2
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI